title: Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.
abstract: OBJECTIVE
  To evaluate the relationship of total-dose of daunorubicin (DNR) to the induction therapy and treatment outcome, we have administered individualized doses of DNR during induction treatment to patients with acute myelogenous leukemia (AML).
  
  
  METHODS
  Ninety-two previously untreated adult patients with AML who entered our hospital were analyzed for the dose of DNR required to achieve complete remission (CR), the CR rate, disease-free survival (DFS), and overall survival (OS). Induction therapy consisted of DNR 40 mg/m2 daily intravenously from day 1 until the marrow was hypoplastic, cytarabine (Ara-C), prednisolone (PRD), and/or 6-thioguanine (6-TG).
  
  
  RESULTS
  Eighty-three of 92 patients with adult AML were assessable for this study. Sixty-three (76%) patients achieved CR. Fifty-two of 63 CR patients achieved the CR in the first course of induction therapy, and 11 patients required the second course of induction therapy. The 5-year and 10-year DFS rates were 31.2% and 5-year and 10-year OS rates were 45.1% and 42.3%, respectively. The median total dose of DNR in the induction therapy was 280 mg/m2 (120 to 480 mg/m2). DNR dose did not influence the response to therapy and was not influenced by the initial WBC count or French-American-British (FAB) system classification.
  
  
  CONCLUSIONS
  These results indicated that when the dose was linked to observed tumor response, the optimal dose of DNR in the induction therapy was approximately 280 mg/m2 (40 mg/m2 for 7 days), which is greater than the conventional dose of 40 to 60 mg/m2 for 3 days.
authors.affiliation: Division of Hematology and Oncology, Jikei University Hospital, Jikei University School of Medicine, Tokyo, Japan. nrk-usui@sa2.so-net.or.jp
authors.forename: N
authors.initials: N
authors.lastname: Usui
authors.forename: N
authors.initials: N
authors.lastname: Dobashi
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Yano
authors.forename: N
authors.initials: N
authors.lastname: Maki
authors.forename: O
authors.initials: O
authors.lastname: Asai
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: H
authors.initials: H
authors.lastname: Watanabe
authors.forename: A
authors.initials: A
authors.lastname: Kato
authors.forename: A
authors.initials: A
authors.lastname: Ogihara
authors.forename: M
authors.initials: M
authors.lastname: Katori
authors.forename: M
authors.initials: M
authors.lastname: Nagamine
authors.forename: Y
authors.initials: Y
authors.lastname: Takei
authors.forename: H
authors.initials: H
authors.lastname: Yamazaki
authors.forename: S
authors.initials: S
authors.lastname: Funakoshi
authors.forename: N
authors.initials: N
authors.lastname: Tajima
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kuraishi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D006331:Heart Diseases / Q000209:etiology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D003630:Daunorubicin